Market capitalization | GBP904.38m |
Enterprise Value | GBP948.30m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 173.05 |
EV/Sales (TTM) EV/Sales | 1.02 |
P/S ratio (TTM) P/S ratio | 0.97 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 5.76% |
Revenue (TTM) Revenue | GBP929.64m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
8 Analysts have issued a Indivior forecast:
8 Analysts have issued a Indivior forecast:
Dec '24 |
+/-
%
|
||
Revenue | 930 930 |
6%
6%
|
|
Gross Profit | 768 768 |
7%
7%
|
|
EBITDA | 241 241 |
519%
519%
|
EBIT (Operating Income) EBIT | 219 219 |
1,226%
1,226%
|
Net Profit | -29 -29 |
790%
790%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Head office | United Kingdom |
CEO | Joseph Ciaffoni |
Employees | 1,051 |
Founded | 2014 |
Website | indivior.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.